BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 25590273)

  • 1. Viremia copy-years as a predictive marker of all-cause mortality in HIV-1-infected patients initiating a protease inhibitor-containing antiretroviral treatment.
    Chirouze C; Journot V; Le Moing V; Raffi F; Piroth L; Reigadas S; Cassuto JP; Chêne G; Leport C; Hoen B;
    J Acquir Immune Defic Syndr; 2015 Feb; 68(2):204-8. PubMed ID: 25590273
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low-level viraemia, measured as viraemia copy-years, as a prognostic factor for medium-long-term all-cause mortality: a MASTER cohort study.
    Quiros-Roldan E; Raffetti E; Castelli F; Focà E; Castelnuovo F; Di Pietro M; Gagliardini R; Gori A; Saracino A; Fornabaio C; Sighinolfi L; Di Filippo E; Maggiolo F; Donato F
    J Antimicrob Chemother; 2016 Dec; 71(12):3519-3527. PubMed ID: 27543658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Copy-Years Viremia and Risk of Virological Failure in Long-Term-Treated HIV Patients.
    Falasca F; De Vito C; Mazzuti L; di Carlo D; Celani L; Fimiani C; dʼEttorre G; Mezzaroma I; Antonelli G; Turriziani O
    J Acquir Immune Defic Syndr; 2019 Apr; 80(4):423-428. PubMed ID: 30531307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determinants of viremia copy-years in people with HIV/AIDS after initiation of antiretroviral therapy.
    Wright ST; Hoy J; Mulhall B; Oʼconnor CC; Petoumenos K; Read T; Smith D; Woolley I; Boyd MA
    J Acquir Immune Defic Syndr; 2014 May; 66(1):55-64. PubMed ID: 24463783
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Viremia copy-years and mortality among combination antiretroviral therapy-initiating HIV-positive individuals: how much viral load history is enough?
    Wang R; Haberlen SA; Palella FJ; Mugavero MJ; Margolick JB; Macatangay BJC; Martínez-Maza O; Jacobson LP; Abraham AG
    AIDS; 2018 Nov; 32(17):2547-2556. PubMed ID: 30379686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Viremia copy-years predicts mortality among treatment-naive HIV-infected patients initiating antiretroviral therapy.
    Mugavero MJ; Napravnik S; Cole SR; Eron JJ; Lau B; Crane HM; Kitahata MM; Willig JH; Moore RD; Deeks SG; Saag MS;
    Clin Infect Dis; 2011 Nov; 53(9):927-35. PubMed ID: 21890751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes.
    Ledergerber B; Lundgren JD; Walker AS; Sabin C; Justice A; Reiss P; Mussini C; Wit F; d'Arminio Monforte A; Weber R; Fusco G; Staszewski S; Law M; Hogg R; Lampe F; Gill MJ; Castelli F; Phillips AN;
    Lancet; 2004 Jul 3-9; 364(9428):51-62. PubMed ID: 15234856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytomegalovirus viremia in Thai HIV-infected patients on antiretroviral therapy: prevalence and associated mortality.
    Durier N; Ananworanich J; Apornpong T; Ubolyam S; Kerr SJ; Mahanontharit A; Ferradini L; Ruxrungtham K; Avihingsanon A
    Clin Infect Dis; 2013 Jul; 57(1):147-55. PubMed ID: 23511301
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Pregnancy on Response to Antiretroviral Therapy in HIV-Infected African Women.
    Kourtis AP; Wiener J; King CC; Heffron R; Mugo NR; Nanda K; Pyra M; Donnell D; Celum C; Lingappa JR; Baeten JM;
    J Acquir Immune Defic Syndr; 2017 Jan; 74(1):38-43. PubMed ID: 27787340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cumulative HIV Viremia Copy-Years and Hypertension in People Living with HIV.
    Xu Y; Chen X; Wijayabahu A; Zhou Z; Yu B; Spencer EC; Cook RL
    Curr HIV Res; 2020; 18(3):143-153. PubMed ID: 32003696
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Viral load monitoring and antiretroviral treatment outcomes in a pediatric HIV cohort in Ghana.
    Kukoyi O; Renner L; Powell J; Barry O; Prin M; Kusah J; Cong X; Paintsil E
    BMC Infect Dis; 2016 Feb; 16():58. PubMed ID: 26843068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical progression of HIV-1 infection according to the viral response during the first year of antiretroviral treatment. Groupe d'Epidémiologie du SIDA en Aquitaine (GECSA).
    Thiébaut R; Morlat P; Jacqmin-Gadda H; Neau D; Mercié P; Dabis F; Chêne G
    AIDS; 2000 May; 14(8):971-8. PubMed ID: 10853978
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Limiting Cumulative HIV Viremia Copy-Years by Early Treatment Reduces Risk of AIDS and Death.
    Olson AD; Walker AS; Suthar AB; Sabin C; Bucher HC; Jarrin I; Moreno S; Perez-Hoyos S; Porter K; Ford D;
    J Acquir Immune Defic Syndr; 2016 Sep; 73(1):100-8. PubMed ID: 27116045
    [TBL] [Abstract][Full Text] [Related]  

  • 14. "Discordant" increases in CD4 cell count relative to plasma viral load in a closely followed cohort of patients initiating antiretroviral therapy.
    Wood E; Hogg RS; Yip B; Tyndall MW; Sherlock CH; Harrigan RP; O'Shaughnessy MV; Montaner JS
    J Acquir Immune Defic Syndr; 2002 Jun; 30(2):159-66. PubMed ID: 12045678
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of low-level viremia on clinical and virological outcomes in treated HIV-1-infected patients.
    ; Vandenhende MA; Ingle S; May M; Chene G; Zangerle R; Van Sighem A; Gill MJ; Schwarze-Zander C; Hernandez-Novoa B; Obel N; Kirk O; Abgrall S; Guest J; Samji H; D'Arminio Monforte A; Llibre JM; Smith C; Cavassini M; Burkholder GA; Shepherd B; Crane HM; Sterne J; Morlat P
    AIDS; 2015 Jan; 29(3):373-83. PubMed ID: 25686685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune Reconstitution in Severely Immunosuppressed Antiretroviral-Naive HIV-1-Infected Patients Starting Efavirenz, Lopinavir-Ritonavir, or Atazanavir-Ritonavir Plus Tenofovir/Emtricitabine: Final 48-Week Results (The Advanz-3 Trial).
    Miro JM; Manzardo C; Ferrer E; Loncà M; Guardo AC; Podzamczer D; Domingo P; Curran A; Clotet B; Cruceta A; Lozano F; Pérez I; Plana M; Gatell JM;
    J Acquir Immune Defic Syndr; 2015 Jun; 69(2):206-15. PubMed ID: 25831464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment Failure in HIV-Infected Children on Second-line Protease Inhibitor-Based Antiretroviral Therapy.
    Suaysod R; Ngo-Giang-Huong N; Salvadori N; Cressey TR; Kanjanavanit S; Techakunakorn P; Krikajornkitti S; Srirojana S; Laomanit L; Chalermpantmetagul S; Lallemant M; Le Cœur S; McIntosh K; Traisathit P; Jourdain G
    Clin Infect Dis; 2015 Jul; 61(1):95-101. PubMed ID: 25838288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Virological remission after antiretroviral therapy interruption in female African HIV seroconverters.
    Gossez M; Martin GE; Pace M; Ramjee G; Premraj A; Kaleebu P; Rees H; Inshaw J; Stöhr W; Meyerowitz J; Hopkins E; Jones M; Hurst J; Porter K; Babiker A; Fidler S; Frater J;
    AIDS; 2019 Feb; 33(2):185-197. PubMed ID: 30325764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors associated with clinical progression in HIV-2 infected-patients: the French ANRS cohort.
    Matheron S; Pueyo S; Damond F; Simon F; Leprêtre A; Campa P; Salamon R; Chêne G; Brun-Vezinet F;
    AIDS; 2003 Dec; 17(18):2593-601. PubMed ID: 14685053
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia.
    Deeks SG; Wrin T; Liegler T; Hoh R; Hayden M; Barbour JD; Hellmann NS; Petropoulos CJ; McCune JM; Hellerstein MK; Grant RM
    N Engl J Med; 2001 Feb; 344(7):472-80. PubMed ID: 11172188
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.